# A governance-first validation framework for human-governed patient safety intelligence platforms

## Structured Abstract

### Objectives

To define a governance-first validation framework for real-time patient safety intelligence systems that integrates policy lifecycle control, human oversight, staged evidence generation, and operational accountability.

### Materials and Methods

We performed a blueprint-centered governance synthesis using the SentinelCare founder blueprint as the primary design source and mapped its governance assumptions to current patient safety strategy, FDA clinical decision support guidance, Good Machine Learning Practice principles, ONC decision support transparency expectations, and real-world external validation literature for clinical prediction systems.

### Results

The resulting framework specifies runtime governance artifacts, explicit policy state transitions, human-review requirements, override logging, rollback capability, and a staged validation pathway consisting of retrospective benchmarking, silent prospective validation, controlled live pilot, and conditional scale-up. It also defines a minimum safety control set and governance metrics spanning harmful false positives, no-action-after-alert rate, override behavior, closure completeness, escalation latency, alert burden by role, and change impact after policy updates.

### Discussion

This framework addresses a recurrent weakness in digital patient safety implementations: governance and validation are often treated as downstream compliance exercises rather than as operating safety controls. Embedding them into runtime system design improves trustworthiness, reduces unmanaged workflow burden, and creates an auditable basis for safe adaptation. The approach is especially important where systems may influence urgent clinical action yet remain highly context-sensitive across sites.

### Conclusion

A governance-first validation framework provides the conditions under which patient safety intelligence can be deployed with accountability, transparency, and adaptive control. It is a prerequisite for trustworthy multidomain scale-up.

## Background and Significance

Clinical intelligence systems are often judged first on analytic performance and only later on operational safety. That ordering is risky in patient safety contexts. A model or rule set can appear promising in development yet still create harm if it is poorly calibrated to local workflow, generates excessive burden, lacks version control, or influences clinicians without adequate transparency and oversight. Recent external validations of widely implemented sepsis models have shown substantial variation in performance across settings, highlighting the limits of assuming transportability or real-world readiness from development claims alone.[1,2]

This problem is not confined to machine learning. Medication CDS literature has repeatedly shown that even technically valid alerts may be ignored, overridden, or operationally counterproductive when specificity, ownership, and user interaction design are weak.[3-5] Diagnostic safety literature likewise demonstrates that failure often arises not from a missing signal alone but from weak follow-up, responsibility diffusion, and lack of verified closure.[6] These findings suggest that patient safety technologies should be governed as operational interventions, not just as computational artifacts.

Policy and regulatory directions reinforce that conclusion. WHO and IHI patient safety strategies both emphasize infrastructure, leadership, accountability, and learning as core requirements for safer systems.[7-9] The January 2026 FDA Clinical Decision Support Software guidance further clarifies intended-use boundaries and the role of clinician review in CDS.[10] FDA Good Machine Learning Practice principles emphasize lifecycle control, monitoring, and change management.[11] ONC Decision Support Interventions requirements emphasize source attribution, transparent intervention logic, and feedback pathways.[12] Together, these sources imply that governance is not an administrative afterthought. It is part of safe design.

The SentinelCare blueprint was built around that premise. It includes approval workflows, policy and model versioning, audit logs, release gates, validation phases, override capture, and rollback controls as core system functions. This manuscript formalizes those elements into a governance-first validation framework for patient safety intelligence platforms.

## Objectives

This study had four objectives:

1. to identify the minimum runtime governance controls required for actionable patient safety intelligence;
2. to define explicit policy lifecycle states and approval structure;
3. to specify a staged validation pathway from retrospective benchmarking to conditional scale-up; and
4. to define governance metrics that expose unsafe, low-value, or non-accountable deployment.
## Materials and Methods

### Design source

The primary source was the SentinelCare founder blueprint, particularly its governance, validation, learning, and deployment sections. Those sections described policy management, override capture, staged rollout, role accountability, and auditability requirements.

### Review strategy

We conducted a targeted framework review updated to March 7, 2026. Sources were selected from 5 categories:

1. patient safety governance strategy;
2. CDS and software regulation;
3. machine learning lifecycle guidance;
4. transparency and intervention requirements in health IT; and
5. empirical evidence on model transportability and implementation burden.

Priority was given to official guidance and high-impact primary studies. The aim was to derive a practical governance and validation model for system design, not to generate a legal or regulatory classification memorandum.

### Analytic approach

Blueprint governance elements were mapped against 4 operational questions:

1. what controls must exist before high-risk alerting is allowed to influence workflow;
2. how policy and model lifecycle states should be represented in the running system;
3. how validation should advance from offline testing to live deployment; and
4. what operational metrics best reveal unsafe or low-value deployment.

A governance component was retained if it satisfied at least 1 of three functions: preventing unsafe activation, enabling accountable postdeployment review, or supporting safe adaptation over time.

### Prototype linkage

We examined whether the proposed governance model could be instantiated in the existing SentinelCare prototype. The current prototype includes policy submission and approval objects, queue items, escalation structures, validation reports, and review actions. These features were used as formative proof of implementability rather than as evidence of real-world governance maturity.

## Results

### Governance as a runtime safety function

The core result is that governance should be represented in the live operating system, not only in committee records. A patient safety intelligence platform should be able to answer, at runtime:

1. which rule, threshold, or model version is active;
2. who approved it;
3. what evidence supported activation;
4. what alerts and overrides occurred under that version; and
5. whether the logic can be withdrawn immediately if problems emerge.

Without this capability, postdeployment learning is weak, attribution is unreliable, and safety incidents cannot be mapped cleanly to accountable design decisions.

### Human oversight requirements

The framework specifies minimum human-review requirements for high-risk use:

1. explicit owner assignment for every actionable alert;
2. mandatory human adjudication for severe or highly interruptive interventions;
3. structured override capture with rationale;
4. periodic review of override distributions, harmful false positives, and missed-event patterns.

This structure reduces unchecked automation bias and creates a formal channel through which disagreement with system output becomes governance data rather than noise.

### Policy lifecycle model

The framework defines 5 policy states:

1. `draft`;
2. `pending approval`;
3. `approved active`;
4. `approved inactive or superseded`; and
5. `retired`.

These states provide a practical change-control model for local policy adaptation, pilot-specific activation, and historical audit. They also make it possible to distinguish experimentation from sanctioned live logic.

### Four-stage validation pathway

Validation is organized into 4 sequential stages.

`Stage 1: retrospective benchmarking.` Candidate logic is tested offline against historical data or curated cases to estimate rule fidelity, event capture, subgroup behavior, and obvious failure modes.

`Stage 2: silent prospective validation.` The system observes live workflow without interrupting care. This stage estimates real-world alert burden, timing, queue accumulation, and mismatch between technical signal and operational usefulness.

`Stage 3: controlled live pilot.` Live use is bounded to a limited setting with mandatory governance review cadence, tighter escalation rules, and explicit authority boundaries.

`Stage 4: conditional scale-up.` Expansion depends on demonstrated performance stability, tolerable burden, governance maturity, and monitoring capability for drift and differential impact.

### Minimum safety control set

The synthesis produced a minimum deployable control set:

1. evidence-bearing alerts only;
2. source transparency and explainability;
3. owner and deadline attached to every actionable alert;
4. queue and escalation state tracking;
5. override capture and review;
6. versioned policy activation;
7. rollback or kill-switch capability; and
8. validation artifact generation before broad deployment.

This set distinguishes a governable patient safety system from a loosely supervised alert engine.
### Governance metrics

The framework recommends operational governance measures rather than approval counts alone:

1. harmful false-positive rate;
2. no-action-after-alert rate;
3. override rate and override-rationale distribution;
4. closure completeness;
5. escalation latency;
6. alert burden by role; and
7. change impact after policy or threshold updates.

These metrics reveal whether a system is safe to operate, not merely whether it is technically functional.

## Discussion

This framework argues that governance is part of the mechanism of safety rather than a surrounding administrative wrapper. That is a consequential design position. It means that patient safety systems should not be allowed to enter live workflow unless they can prove what logic is active, who approved it, how clinicians can disagree with it, and how problematic logic can be withdrawn. This becomes more important, not less, as systems become broader in scope and more capable of issuing urgent recommendations.

The framework is also grounded in real deployment lessons. Sepsis-model external validations show that transportability cannot be assumed and that local context matters materially.[1,2] Medication alerting evidence shows that overload and poor specificity can degrade value even when underlying logic is technically sound.[3-5] Diagnostic safety work shows that acknowledgement is not enough without follow-up and closure.[6] A governance-first architecture does not eliminate these problems, but it turns them into measurable, reviewable operating conditions.

This work also clarifies how patient safety intelligence should be positioned relative to AI governance. The useful question is not whether every system should be marketed as AI. The useful question is whether the system can satisfy transparency, intended-use discipline, lifecycle control, and accountable human oversight when it influences clinical workflow. The framework presented here was designed to satisfy those higher-level requirements irrespective of whether a specific module is purely rule-based, predictive, or hybrid.

The framework has limitations. It is not a substitute for local institutional review, product-specific regulatory assessment, or prospective clinical-effectiveness evidence. Some controls, particularly drift monitoring and fairness surveillance, require data maturity beyond early pilots. Nevertheless, the framework provides the necessary operating structure before those later stages can be justified.

The immediate implication is practical. Patient safety intelligence systems should be built and evaluated as governed operational programs. Systems that do not include version control, override review, staged validation, and rollback capability should be considered immature regardless of their apparent analytic sophistication.

## Conclusion

Governance and validation are core safety mechanisms for patient safety intelligence systems. A governance-first framework makes it possible to deploy patient safety logic with accountability, transparency, and adaptive control while limiting the risks of unmanaged burden, automation bias, and opaque change. That framework is a prerequisite for trustworthy multidomain scale-up.

## Funding

[Insert funding statement]

## Acknowledgments

The authors acknowledge the blueprint development and governance synthesis work that informed this framework.

If applicable at submission, include an AI-use disclosure consistent with journal policy.

## Conflict of Interest

[Insert conflict of interest statement]

## Data Availability

No patient-level dataset is reported in this framework paper. Non-sensitive project materials and prototype artifacts are available in the public repository: https://github.com/hssling/sentinelcare-mvp

## References

1. Wong A, Otles E, Donnelly JP, et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021;181(8):1065-1070.
2. Apalodimas L, Meyer AN, Ali T, et al. External validation in county emergency departments of a widely implemented sepsis prediction model. JAMIA Open. 2024;7(4):ooae116.
3. Slight SP, Beeler PE, Seger DL, et al. A cross-sectional observational study of high override rates of drug allergy alerts in inpatient and outpatient settings, and opportunities for improvement. BMJ Qual Saf. 2017;26(3):217-225.
4. Nanji KC, Seger DL, Slight SP, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc. 2018;25(5):476-481.
5. Bates DW, Kuperman GJ, Wang S, et al. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J Am Med Inform Assoc. 2003;10(6):523-530.
6. Callen J, Georgiou A, Li J, Westbrook JI. Closing the loop on test results to reduce communication failures: a rapid review of evidence, practice and patient perspectives. BMC Health Serv Res. 2020;20:897.
7. World Health Organization. Global patient safety action plan 2021-2030: towards eliminating avoidable harm in health care. Geneva, Switzerland: World Health Organization; 2021.
8. World Health Organization. Global patient safety report 2024. Geneva, Switzerland: World Health Organization; 2024.
9. Institute for Healthcare Improvement. Safer together: a national action plan to advance patient safety. Boston, MA: IHI; 2022.
10. US Food and Drug Administration. Clinical decision support software: guidance for industry and Food and Drug Administration staff. Silver Spring, MD: FDA; January 2026.
11. US Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency. Good machine learning practice for medical device development: guiding principles. Silver Spring, MD: FDA; 2021.
12. Office of the National Coordinator for Health Information Technology. Decision support interventions. Washington, DC: ONC Health IT Certification Program; accessed March 7, 2026.
